Acute glycaemic effects of co-trimoxazole at prophylactic dose in healthy adults

Simple item page
dc.contributor.authorKenteu, Bernold
dc.contributor.authorNoubiap, Jean Jacques N
dc.contributor.authorEtoa, Martine Claude
dc.contributor.authorAzabji-Kenfack, Marcel
dc.contributor.authorDehayem, Mesmin
dc.contributor.authorSobngwi, Eugène
dc.date.accessioned2021-10-08T06:20:19Z
dc.date.available2021-10-08T06:20:19Z
dc.date.issued2016
dc.description.abstractAbstract Background Cases of severe hypoglycaemia were reported in HIV/AIDS patients receiving high dose of the sulfonylurea co-trimoxazole for opportunistic infections. Whether co-trimoxazole at prophylactic dose would induce similar side effects is unknown. We aimed to investigate the acute effects of co-trimoxazole at prophylactic dose on glucose metabolism in healthy adults. Methods We enrolled 20 healthy volunteers (15 males and 5 females) aged 23.0 (SD 2.0) years, with mean BMI of 22.3 (SD 3.6) Kg/m 2 with normal glucose tolerance, hepatic and renal function. We performed a 75-g oral glucose tolerance test (OGTT) with and without concomitant oral co-trimoxazole administered 60 min before the test. Blood glucose response was measured using a capillary test at baseline and at 30, 60, 90, 120 and 180 min following oral glucose load on the two occasions. C-peptide response was also measured. Absolute values of blood glucose and C-peptide with and without co-trimoxazole were compared using the Wilcoxon test. Results During the OGTT without co-trimoxazole (control) vs. the OGTT with co-trimoxazole (test), the glycaemia varied from 4.83 (SD 0.39) mmol/l vs. 4.72 (SD 0.28) mmol/l at T0 (P = 0.667), to 8.00 (SD 1.11) mmol/l vs. 7.44 (SD 0.78) mmol/l at T30 (P = 0.048), 8.00 (SD 1.17) mmol/l vs. 7.67 (SD 1.00) mmol/l at T60 (P = 0.121), 7.33 (SD 0.94) mmol/l vs. 7.11 (SD 0.83) mmol/l at T90 (P = 0.205), 6.78 (SD 1.00) mmol/l vs. 6.67 (SD 1.00) mmol/l at T120 (P = 0.351) and 4.72 (SD 1.39) mmol/l vs. 4.72 (SD 1.56) mmol/l at T180 (P = 0.747). The ratio of area under the glycaemia curve during the control and test investigation was 96.7 %, thus a 3.3 decreased glycaemic response (p = 0.062). A decrease of glycaemia by more than 10 % occurred in 6/20 participants at T30, 7/20 participants at T60 and 1/20 participant at T30 and T60. None of the volunteers experienced co-trimoxazole-induced hypoglycaemia. At the same time, the C-peptide response during the control vs. the test investigation varied from 278.1 (SD 57.5) pmol/l vs. 242.8 (SD 42.5) pmol/l at T0 (P = 0.138), to 1845.6 (SD 423.6) pmol/l vs. 2340.6 (SD 701.3) pmol/l at T60 (P = 0.345) and 1049.8 (SD 503.1) pmol/l vs. 1041.63 (SD 824.21) pmol/l at T180 (P = 0.893). Conclusion Ninety minutes after its administration, co-trimoxazole induced a significant reduction of the early glycaemic response to oral glucose in parallel with a 27-% increase in insulin secretory response. Co-trimoxazole induced within 120 min a more than 10-% blood glucose reduction in 2/3 of participants. However none of the volunteers experienced hypoglycaemia.
dc.identifier.apacitationKenteu, B., Noubiap, J. J. N., Etoa, M. C., Azabji-Kenfack, M., Dehayem, M., & Sobngwi, E. (2016). Acute glycaemic effects of co-trimoxazole at prophylactic dose in healthy adults. <i>BMC Endocrine Disorders</i>, 16(1), 174 - 177. http://hdl.handle.net/11427/34252en_ZA
dc.identifier.chicagocitationKenteu, Bernold, Jean Jacques N Noubiap, Martine Claude Etoa, Marcel Azabji-Kenfack, Mesmin Dehayem, and Eugène Sobngwi "Acute glycaemic effects of co-trimoxazole at prophylactic dose in healthy adults." <i>BMC Endocrine Disorders</i> 16, 1. (2016): 174 - 177. http://hdl.handle.net/11427/34252en_ZA
dc.identifier.citationKenteu, B., Noubiap, J.J.N., Etoa, M.C., Azabji-Kenfack, M., Dehayem, M. & Sobngwi, E. 2016. Acute glycaemic effects of co-trimoxazole at prophylactic dose in healthy adults. <i>BMC Endocrine Disorders.</i> 16(1):174 - 177. http://hdl.handle.net/11427/34252en_ZA
dc.identifier.issn1472-6823
dc.identifier.ris TY - Journal Article AU - Kenteu, Bernold AU - Noubiap, Jean Jacques N AU - Etoa, Martine Claude AU - Azabji-Kenfack, Marcel AU - Dehayem, Mesmin AU - Sobngwi, Eugène AB - Abstract Background Cases of severe hypoglycaemia were reported in HIV/AIDS patients receiving high dose of the sulfonylurea co-trimoxazole for opportunistic infections. Whether co-trimoxazole at prophylactic dose would induce similar side effects is unknown. We aimed to investigate the acute effects of co-trimoxazole at prophylactic dose on glucose metabolism in healthy adults. Methods We enrolled 20 healthy volunteers (15 males and 5 females) aged 23.0 (SD 2.0) years, with mean BMI of 22.3 (SD 3.6) Kg/m 2 with normal glucose tolerance, hepatic and renal function. We performed a 75-g oral glucose tolerance test (OGTT) with and without concomitant oral co-trimoxazole administered 60 min before the test. Blood glucose response was measured using a capillary test at baseline and at 30, 60, 90, 120 and 180 min following oral glucose load on the two occasions. C-peptide response was also measured. Absolute values of blood glucose and C-peptide with and without co-trimoxazole were compared using the Wilcoxon test. Results During the OGTT without co-trimoxazole (control) vs. the OGTT with co-trimoxazole (test), the glycaemia varied from 4.83 (SD 0.39) mmol/l vs. 4.72 (SD 0.28) mmol/l at T0 (P = 0.667), to 8.00 (SD 1.11) mmol/l vs. 7.44 (SD 0.78) mmol/l at T30 (P = 0.048), 8.00 (SD 1.17) mmol/l vs. 7.67 (SD 1.00) mmol/l at T60 (P = 0.121), 7.33 (SD 0.94) mmol/l vs. 7.11 (SD 0.83) mmol/l at T90 (P = 0.205), 6.78 (SD 1.00) mmol/l vs. 6.67 (SD 1.00) mmol/l at T120 (P = 0.351) and 4.72 (SD 1.39) mmol/l vs. 4.72 (SD 1.56) mmol/l at T180 (P = 0.747). The ratio of area under the glycaemia curve during the control and test investigation was 96.7 %, thus a 3.3 decreased glycaemic response (p = 0.062). A decrease of glycaemia by more than 10 % occurred in 6/20 participants at T30, 7/20 participants at T60 and 1/20 participant at T30 and T60. None of the volunteers experienced co-trimoxazole-induced hypoglycaemia. At the same time, the C-peptide response during the control vs. the test investigation varied from 278.1 (SD 57.5) pmol/l vs. 242.8 (SD 42.5) pmol/l at T0 (P = 0.138), to 1845.6 (SD 423.6) pmol/l vs. 2340.6 (SD 701.3) pmol/l at T60 (P = 0.345) and 1049.8 (SD 503.1) pmol/l vs. 1041.63 (SD 824.21) pmol/l at T180 (P = 0.893). Conclusion Ninety minutes after its administration, co-trimoxazole induced a significant reduction of the early glycaemic response to oral glucose in parallel with a 27-% increase in insulin secretory response. Co-trimoxazole induced within 120 min a more than 10-% blood glucose reduction in 2/3 of participants. However none of the volunteers experienced hypoglycaemia. DA - 2016 DB - OpenUCT DP - University of Cape Town IS - 1 J1 - BMC Endocrine Disorders LK - https://open.uct.ac.za PY - 2016 SM - 1472-6823 T1 - Acute glycaemic effects of co-trimoxazole at prophylactic dose in healthy adults TI - Acute glycaemic effects of co-trimoxazole at prophylactic dose in healthy adults UR - http://hdl.handle.net/11427/34252 ER - en_ZA
dc.identifier.urihttp://hdl.handle.net/11427/34252
dc.identifier.vancouvercitationKenteu B, Noubiap JJN, Etoa MC, Azabji-Kenfack M, Dehayem M, Sobngwi E. Acute glycaemic effects of co-trimoxazole at prophylactic dose in healthy adults. BMC Endocrine Disorders. 2016;16(1):174 - 177. http://hdl.handle.net/11427/34252.en_ZA
dc.language.isoeng
dc.publisher.departmentDepartment of Medicine
dc.publisher.facultyFaculty of Health Sciences
dc.sourceBMC Endocrine Disorders
dc.source.journalissue1
dc.source.journalvolume16
dc.source.pagination174 - 177
dc.source.urihttps://dx.doi.org/10.1186/s12902-016-0142-6
dc.subject.otherAdults
dc.subject.otherCo-trimoxazole
dc.subject.otherGlycaemia
dc.subject.otherAdult
dc.subject.otherBlood Glucose
dc.subject.otherBody Mass Index
dc.subject.otherFemale
dc.subject.otherGlucose
dc.subject.otherGlucose Tolerance Test
dc.subject.otherHumans
dc.subject.otherHypoglycemia
dc.subject.otherMale
dc.subject.otherPre-Exposure Prophylaxis
dc.subject.otherTrimethoprim, Sulfamethoxazole Drug Combination
dc.subject.otherBlood Glucose
dc.subject.otherTrimethoprim, Sulfamethoxazole Drug Combination
dc.subject.otherGlucose
dc.titleAcute glycaemic effects of co-trimoxazole at prophylactic dose in healthy adults
dc.typeJournal Article
uct.type.publicationResearch
uct.type.resourceJournal Article
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
KenteuBernold_Acute_glycaemic_2016.pdf
Size:
496.19 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Journal Articles